Biosimilars in pediatric rheumatology and their introduction into routine care by Cuevas, Octavio Aragon & Hedrich, Christian M
Journal Pre-proof
Biosimilars in pediatric rheumatology and their introduction into
routine care




To appear in: Clinical Immunology
Received date: 17 March 2020
Revised date: 24 April 2020
Accepted date: 24 April 2020
Please cite this article as: O.A. Cuevas and C.M. Hedrich, Biosimilars in pediatric
rheumatology and their introduction into routine care, Clinical Immunology (2019),
https://doi.org/10.1016/j.clim.2020.108447
This is a PDF file of an article that has undergone enhancements after acceptance, such
as the addition of a cover page and metadata, and formatting for readability, but it is
not yet the definitive version of record. This version will undergo additional copyediting,
typesetting and review before it is published in its final form, but we are providing this
version to give early visibility of the article. Please note that, during the production
process, errors may be discovered which could affect the content, and all legal disclaimers
that apply to the journal pertain.
© 2019 Published by Elsevier.
Biosimilars in Pediatric Rheumatology and their introduction into routine care 
Octavio Aragon Cuevas 1, Christian M. Hedrich2 
 
1 Pharmacy Department, Alder Hey Children’s NHS Foundation Trust, Liverpool, United 
Kingdom 
2 Department of Women's & Children's Health, Institute of Translational Medicine, 
University of Liverpool, Liverpool, UK & Department of Pediatric Rheumatology, Alder 
Hey Children's NHS Foundation Trust Hospital, Liverpool, UK 
 
Please address correspondence to: 
Octavio Aragon Cuevas 
Pharmacy Department, Alder Hey Children’s NHS Foundation Trust. 
East Prescot Road 














Biosimilars are biologic medications that are slightly altered versions of already approved 
biologic disease modifying anti-rheumatic drugs (bDMARDs). They can be manufactured 
after the original product's patent protection expires. The advent of biosimilar use in pediatric 
rheumatology started with the biosimilar to infliximab in 2013. Since then, more biosimilars 
have been made available including etanercept, rituximab and adalimumab. This manuscript 
briefly reviews the history of biosimilar introduction to treatment and suggests strategies for 
the adoption of biosimilar drugs in services specialized in Pediatric Rheumatology, including 
potential barriers and solutions to their implementation into practice. The review covers 
general aspects relevant to all biosimilar drugs and specific examples covering individual 
drugs based on the experience of a large tertiary Pediatric Rheumatology service in the 
Northwest of England. 
 
Keywords: 
Biosimilar, Children, Rheumatology, Pediatrics, Treatment 
 
Funding: 
This research did not receive any specific grant from funding agencies in the public, 













The use of monoclonal antibodies (mAbs) has become a key component in the differential 
treatment of pediatric autoimmune/inflammatory conditions since the etanercept originator 
product Enbrel® was made available in the European market for the treatment of Juvenile 
Idiopathic Arthritis (JIA) in 1999. Biologic or biopharmaceutical products are defined by 
their synthesis being manufactured in, extracted from, or semi-synthesized from biological 
sources. Based on this, the European Medicines Agency (EMA) defines them as “medicines 
derived from living cells or organisms, consisting of large highly complex molecular entities 
which may be difficult to characterize”[1]. They are structurally complex, diverse between 
individual agents, and may have several functional domains within a single molecule. 
Biologics share key properties, including being toxic to target cells or neutralizing cytokines 
(e.g. TNF, IL-17, IL-6, IL-1, etc.), but may differ in aspects such as the mechanism of action. 
For instance, etanercept is a fusion protein of the Fc region of IgG1 and the extracellular 
domain of the human TNF 2 receptor. It acts as a soluble competitive antagonist of the TNF-
alpha receptor and only binds to free and not receptor bound TNF. Adalimumab on the other 
hand is a recombinant anti-TNF antibody that binds specifically to freely available TNF-
alpha, neutralizing the biological function of TNF by blocking its interaction with the cell 
surface TNF receptors. Thus, adalimumab can also inactivate already receptor bound TNF. 
These differences in chemical structure and mechanism of action can directly affect patient-
related aspects of clinical care; patients and clinicians will have to choose anti-TNF therapies 
between etanercept (given subcutaneously twice a week) and adalimumab (given 
subcutaneously once every 2 weeks). Furthermore, some biologic medicines may be derived 
from animal cell lines, and other from human cell lines; this can lead to differences in the 
levels of immunogenicity within the available products [2,3]. 
 
Over the years, a constantly growing number of biologic disease-modifying anti-rheumatic 
drugs (bDMARDs) have joined etanercept and allow for (some level of) target-directed and 
individualized treatment. The effects of these drugs in inducing and maintaining remission 
have been tangible and in many superior when compared to conventional non-biologic 
DMARDs such as methotrexate or sulphasalazine [4-10]. As a result both rheumatologists 
and the general public have been demanding increased and faster access to these novel drugs. 
However, availability of bDMARDs needs to be considered carefully and balanced in the 
context of finite budgets of public health care systems [11-14]. However, it should be noted 
that, even with lower costs, the use of bDMARDs (may it be the originator or the biosimilar) 
requires critical decision-making, taking side effects such as infections and tumor risk into 
consideration.  
 
The introduction of biosimilar pharmaceuticals to the market in 2013 may have opened the 
door to more widespread access to these “high cost” medicines [11-14]. Biosimilars are 
biologic medications that are on the molecular level very similar to already approved 
bDMARDs and therefore are approved but slightly altered “versions” of the “innovator 
drug”. They can be manufactured after the original product's patent protection expires [15]. 
The European Medicines Agency (EMA) defines a biosimilar medicine as “a biological 
product that is highly similar but not identical, to the licensed originator biological medicine 
and shows no clinically meaningful difference in terms of quality, safety and efficacy” [1].  
From a licensing perspective, biosimilars are approved following similar standards of 
pharmaceutical quality, safety and efficacy that apply to all biological medicines. The 
process, however, is expedited and limited to clinical testing in one of the conditions (and age 











Over the past 5 years, the number of tested and licensed biosimilar mAb products (ending 
with “-mab”) and soluble protein receptor constructs (ending with “-cept”) has increased 
exponentially as patents of originator bDMARDs have started to expire [17-21]. This article 
provides an overview of the introduction of biosimilar medicines in Pediatric Rheumatology 
using a large tertiary Pediatric service in the North West of England as an example (Alder 
Hey Children’s NHS Foundation Trust). We suggest introduction strategies and discuss 
barriers to implementation with drug-specific examples and share a number of lessons 
learned over the last five years. 
 
2. Biosimilar medicines in Pediatric Rheumatology: is extrapolation justified and 
feasible? 
Pediatric practitioners have always been advocates of the sentence “Children are not small 
adults” [22]. We have sadly learned from examples where children have come to harm (grey-
baby syndrome with chloramphenicol in neonates, phocomaelia cases with thalidomide, 
respiratory depression in ultra-rapid codeine metabolizers) that extrapolation from adult 
dosage information is not always feasible. This is due to the potential of pharmacokinetic and 
pharmacodynamic differences in children when compared to young people (adolescents) and 
adults. These differences can lead to significant alterations in the process of drug absorption, 
distribution, metabolism and excretion, which ultimately, if ignored, can negatively affect 
pediatric patients [23-25]. 
For many years, children have been called “therapeutic orphans” due to the lack of 
investment in pediatric research and pediatric clinical trials. In the last 13 years both the Food 
and Drug Association (FDA) in the United States and the EMA, among others, aimed to 
address this imbalance by implementing a number of strategies to increase the number of 
pediatric clinical trials and research in novel medicines with potential pediatric applications. 
They have also encouraged pharmaceutical companies to re-visit traditional active ingredients 
via Pediatric Use Marketing Authorization (PUMA) where Pediatric clinical trials are not 
available by providing incentives such as renewal or extensions of patents [26-27].  However, 
while more Pediatric trials are being performed, advances have been disappointingly slow 
with still only a very small number of Pediatric clinical trials being planned and funded [28].  
The principle of extrapolation claims that comparable structural attributes, biological 
functions, human (not necessarily pediatric) pharmacokinetic and pharmacodynamics 
(PK/PD) between a reference originator product and a biosimilar in a homogenous population 
of patients falling within a sensitive indication allows to apply the principle of “similarity” 
also to all other indications (figure 1) [29,30]. Because of the aforementioned historical 
struggle with Pediatric medicines and challenges associated, a majority of Pediatric 
practitioners found the “principle of extrapolation” a difficult pill to swallow. 
 
A number of assays allow for in-depth characterization of complex proteins, both on a 
physicochemical and a functional level [31]. Through these, structural attributes of the 
originator molecules can be compared and contrasted to biosimilars. Minor alterations and 
resulting differences may be accepted as long as the biological functions of the drug remain 
the same. The basis to support this approach lies in the fact that originator molecules have 
indeed been changed substantially during their patented life [29,30]. For instance, the 
originator molecule infliximab (Remicade®) underwent at least 3 “high risk” manufacturing 
changes that led to variability on the original protein while not resulting in a new licensing 
process and/or clinical trial. In a real-life-scenario, (minor) alterations did not affect the 
efficacy or toxicity of the originator product. Therefore, we may assume that a similar degree 










Nonetheless, and due to the added complexity that pharmaceutical companies face replicating 
complex protein structures, biosimilar medicines need to undergo a more rigorous 
development approach, much closer to the one required for originator medicines than generic 
medicines (figure 2). PK and PD equivalence needs to be demonstrated in humans, and 
biosimilars have to be tested in a clinical trial with a large enough sample population with a 
known indication for the drug. 
 
Unfortunately, the need for like-for-like comparison in children and young people (CYP) was 
not deemed necessary by either the FDA or the EMA. Because of this, Pediatric clinicians 
across the world have been left to deal with these uncertainties as part of real clinical 
practice. 
 
Another risk that many clinicians feel may be undetected by the suggested development 
strategy for biosimilars is the potential of patients developing cross-immunogenicity when 
swapping from an originator product to a biosimilar, or switching between two biosimilars. 
To address this, the UK’s NICE advised that interchangeability of the products cannot be 
assumed, and therefore recommends prescribing of these drugs by brand, avoiding automatic 
substitutions and, in Pediatrics, close clinical monitoring for an initial undefined period [32]. 
A number of studies suggested that the most common switch (i.e. from originator molecule to 
biosimilar) does not affect drug efficacy and safety [33,34]. However, additional data from 
clinical and real-world studies (especially of switching between biosimilars) are required, as 
is continued pharmacovigilance. Thus, any switching between drugs should remain a clinical 
decision made jointly by the treating physician and patients and their families on an 
individual basis supported by scientific evidence, not just resemble a cost-saving exercise 
[32]. To address remaining concerns, prospective immunogenicity testing, long-term 
pharmacovigilance plans and post-marketing studies are needed to, among others, capture 
late adverse events. 
 
3. Suggestion for a pathway to safely implement biosimilar medicine use  
The adoption of biosimilars will help provide much needed savings to national health systems 
and/or insurers and further benefit individualized patient care. However, introduction should 
not be driven purely by financial considerations. 
The purpose of creating a document to guide the adoption of new biosimilar medicines by 
Children’s Hospitals/Trusts is to outline the process involved in the early adoption phase that 
allows early assessment of benefits and potential risks for patients, prescribers and 
Hospitals/Trusts. The ultimate aim is to ensure that the care provided to patients remains 
unaltered, and that the patient experiences no change in the treatment tolerability and efficacy 
[35]. However, we will describe some examples further on where this premise was not fully 
adhered to. A graphical summary of the suggested adoption process is available on Appendix 
A. We suggest that, before initiating adoption of a new biosimilar medicine in the 
department’s portfolio, the pediatric rheumatology multidisciplinary team (MDT), including 
a pharmacist (purchasing and contracts), specialist nurses (administration details) and at least 
one responsible clinician (Pediatric Rheumatologist), review the flowchart and assess if the 
plausibility for the introduction of the drug. 
 
3.1 Initial considerations 
One of the considerations prior to adoption of new biosimilars relevant to pediatric practice 
should include whether the available biosimilar covers the required licensed indications. 
Generally, by definition, biosimilars can only be approved and used for the indications 










EMA and the FDA for the treatment of juvenile idiopathic arthritis (JIA) and therefore 
adoption for this indication should be prioritized. When the new biosimilars for adalimumab 
became available, the FDA and the EMA approved some of them for JIA but not for pediatric 
uveitis, while being approved for anterior uveitis in adults [36]. The indications included 
were reflective of the approved indications of the originator product at the time of initiation 
of biosimilar development. Indeed, licensed indications for a product drive the choice of 
biosimilar (or no biosimilar) adoption, as pediatric good practice prescribing rules advise that 
licensed products should be used first, unless there are individual patient-centered 
circumstances affecting the prescriber’s decision process [37]. Cost reduction should 
generally not be considered as a valid reason on their own to favor off-label and unlicensed 
use of medicines in children over licensed ones [37]. However, pressure from 
insurers/funders, health systems and Hospitals/Trusts certainly influence thought processes in 
real life. 
On the other hand, in cases where the originator product has been used off-label outside 
licensing (examples are rituximab and infliximab in Pediatric Rheumatology), biosimilar 
products (as of now) also will not cover these indications and cannot contribute to the 
generation of evidence towards approval in the respective patient population [32]. However, 
at the same time, the use and clinical assessment of biosimilars for pediatric patients should 
and cannot necessarily be reduced to the license of the originating product as a host of 
treatments are tolerated in children, have proven efficacious in practice while not being 
formally approved. As such, biosimilar medicines may be used off-label in the future for non-
approved conditions. The availability of these drugs to treat non-approved conditions will be 
directly affected by the commissioning processes in the respective countries where the drug is 
being used.  Furthermore, even when the biosimilar medicine has been granted a pediatric 
license, this does not necessarily mean that the product is suitable for pediatric use. This 
could be due to the inclusion of inappropriate excipients in the formulation or due to the 
choice of devices that have been made available. Pharmaceutical companies producing 
etanercept biosimilars to date, for example, have not developed a 10mg strength vial and as 
such are not suitable for use in the younger population group of patients [38,39]. Therefore, 
the type of preparation available (strength, concentrations, formulation, route, administration 
details) also needs to come into play. Tables 1 and 2 show examples of an in-depth 
assessment of the biosimilar products available (etanercept and adalimumab) at the time. 
 
Lastly, embarking in the process of biosimilar adoption is a resource heavy endeavor. 
Departments need to ensure that they factor in time for their relevant multidisciplinary team 
members (specialist nurses, pharmacists, etc.) to develop information and educational tools 
for families and other members of staff, guideline updates and/or amendments and deal with 
any queries from patients and their families pertaining the novel use of biosimilar medicines. 
Some of these tools may be available from pharmaceutical companies. However, in the 
authors’ experience (as Pediatrics is usually a small market) child-friendly educational and 
informative tools do not exist for all originating drugs and/or biosimilars and it may be years 
before become are available. 
 
3.2 Provision of medicines 
In order to maximize potential cost savings associated with the adoption of biosimilars into 
clinical routines, a number of actions may be agreed. In the UK, supplying the drug via 
homecare companies maximizes the cost-efficiency for these expensive drugs (biologics and 
biosimilars alike). Services in the UK will need to establish whether a pharma-funded 
homecare service is offered by manufacturers and whether any extended services are 










regional framework is suitable [35]. Moreover, it is imperative to ascertain whether product-
associated support services available are acceptable to CYP. Most homecare service 
providers will offer some type of community nursing support for administration education, 
but their staff are rarely trained in Pediatrics. Thus, the clinical team and pharmacy providers 
need to assess carefully how important they perceive this is for their specific patient groups. 
More importantly, a homecare team or service should already be available in the 
Rheumatology Service/Hospital/Trust and be able to take on additional patient numbers every 
time a biosimilar product is adopted in the hospital formulary. However, even in well-
established homecare departments and services, the process of initiating a homecare contract 
may be lengthy and the service level agreements drafted by individual homecare companies 
may need to be altered multiple times. 
For drugs that are not suitable for home administration, further checks are necessary. This 
particularly applies to drugs that require being prepared in the Aseptic Services Unit (ASU). 
It has to be considered whether data on drug stability, storage and expiration of the biosimilar 
are the same or comparable to the originator. The Pharmacy Aseptic Team will need to 
develop new worksheets for intravenous biosimilars approved for use within the 
Hospital/Trust. In most cases, extended stability data for the biosimilar may be available from 
the manufacturers and they should always be the first port of call to obtain this information 
[35]. 
Finally, close liaison with the Pharmacy Purchasing Team is required to discuss practical 
matters including anticipated launch dates, regional contracts and pricing information 
(including aforementioned homecare provision services). 
 
3.3 Target patient population 
A decision requires to be made on whether individual biosimilars should be introduced for 
existing patients (switch), new patients only, or both. The authors department’s approach has 
been to trial the biosimilar product in new patients first to gather real-life data on whether a 
small pilot patient population tolerates the new product and shows comparable response rates 
expected from originator drugs. If the trial period (this could be any length of time, in the 
case of bDMARDs usually between 3 to 6 months, depending on the number of patients 
started on these drugs within the service) delivers positive results (with the focus on 
tolerability much for than long-term efficacy at this stage), consideration to switch existing 
patients can go ahead. Moots et al recently reviewed published experience with switching 
from originator biologic to biosimilar evaluating 12 studies that ranged in observation length 
from 24 to 56 weeks [34]. The authors concluded that initial data suggests maintenance of 
efficacy and safety in the absence of increased immunogenicity. Recently, a total of 265 
patients were switched from an originator bDMARD to the respective biosimilar and 
followed for 3 years. After 2 years, 140 patients were switched to a second biosimilar while 
26 remained on the first biosimilar and 55 reverted back to the originator. Analysis showed 
that the number of biosimilars received did not affect antidrug antibodies development [40]. 
Further studies have suggested similar results for most biosimilar drugs [41,42]. 
 
However, continued pharmacovigilance is imperative as, with added biosimilars entering the 
market and potentially different centers purchasing different ones, individual patients may be 
switched between preparations when changing address (for example, transitioning to adult 
services, moving to university or moving to other postcodes or counties). The authors expect 
that once the first disease cohort of patients has successfully switched from originator drug to 
biosimilar, it will be difficult to argue against switching patients when new biosimilars come 
into the market as all these drugs work on similar premises. However, small modifications to 










Thus, the inclusion of patients treated with biosimilars in the available cohort studies such as 
the ‘Biologics for Children with Rheumatic Diseases’ (BCRD) and BSPAR Etanercept Study 
(BSPAR ETN) in the UK (https://sites.manchester.ac.uk/bcrdbspar/) or the BIKER registry in 
Germany (http://www.biker-register.de/). is imperative to obtain a long-term view on whether 
patients on biosimilar medicines indeed clinically respond in a similar way to patients on the 
originator medicines [43]. 
 
3.4 Governance and local approval 
Forms for the use of new drugs should be submitted to local clinical committees. The 
submission document should cover all the points addressed above. Experience from other 
services, published evidence (where available), clinical opinion or reviews should be 
included as evidence [35]. As explained above, it is unlikely that pediatric data will be 
available through randomized controlled trials. At this point a decision should be made on 
which biosimilar the department will be adopting if more than one is available. As a useful 
collateral effect, submitting the evidence to request the addition of a new bDAMRD may 
trigger a review and improvement of the current practice.  
 
3.5 Informing and involving patients 
The UK NICE guidance suggests that the “decision on the requirement to inform new 
patients rests with the individual clinical team once the biosimilar has been approved and 
adopted at the Trust”. It is important to note that, for new patients, the use of a biosimilar will 
not be a change in therapy they need to be informed of, but a recommended treatment like 
any other started by a clinician. Thus, no additional information is needed on top of the usual 
drug related education given to the patient and their families. The focus of developing 
information and educational materials for biosimilar medicines should be for patients 
switching from an originator product to a biosimilar product [35]. How the 
information/education is carried out will be specific for the therapy in question. For example, 
for patients who are coming to the hospital for their treatments, face to face education and 
information should be prioritized.  For patients who are being treated at home, a number of 
possibilities are available (see table 3). 
 
Box 1: Authors’ experience with patient involvement. 
Whether face to face or via letter, a number of points that should be discussed with 
patients and families when switching from an originator medicine to a biosimilar, or 
between to biosimilars: 
1) Explain the reasoning behind the change. Be honest if the change has been driven mainly 
by financial considerations but present it in the context of wider health benefits for the whole 
population if relevant 
2) Explain, in lay terms, what a biosimilar medicine is and how it compares in efficacy and 
safety to the originator molecule or the other biosimilar 
3) Signpost the patient and their family to higher organisms supporting the switch and any 
educational sites they can access to gain further information 
4) Lay out any differences in care the child might expect as a result of the switch 
5) Offer them sufficient time to read and access the information and contact the team with 
any queries or worries they might have. Re-assure them if possible that they will not be 
forced to switch, but make sure that any resistance to change is based on accurate facts and 
not misunderstanding of information. Ultimately, if the families refused to switch, a patient 
centered approach was favored and no patient who was not willing to switch was forced to do 
so. 












3.6 Transition to adult services 
The transitioning process should take into consideration the commissioning position of 
biosimilar pharmaceuticals in adult Rheumatology. Young adults should be supported in 
potential (and likely) switching between drugs whenever possible before the actual transition 
happens. For some young adults, changing teams and care environment may already cause 
concern and/or anxieties. Adding an alteration of the drug and/or device they are using at the 
same time should be avoided whenever possible. However, ultimately this will be the 
decision of the young person, and some of them will choose to stay on their ‘Pediatric 
initiated preparation’ until transition occurs. While this option should certainly be respected, 
patients and families should be informed about the possibility that adult services may not 
have a choice but to switch treatment after transition. Of note, the patient’s treatment 
(including brand names) should be clearly communicated to the adult service to ensure 
continuity of treatment and supply [35]. 
 
3.7 Prescribing requirements and IT readiness 
Another practical aspect to secure a smooth transition to biosimilar medicines includes 
ensuring electronic prescribing systems have been updated to include the new medicines in 
the hospital formulary. NICE in the UK and the EMA have suggested to prescribe biosimilars 
by brand name [1,32]. In the authors’ service biosimilars and any originator medicines are 
prescribed by both their active drug name (international non-proprietary name INN) and the 
brand name in brackets, for example, “Infliximab (Remsima®)”. 
 
3.8 Pharmacovigilance and clinical outcomes monitoring 
By nature, all biologics require close clinical monitoring for safety, and any suspected 
adverse drug reaction (ADR) should be reported to national drug safety authorities providing 
the brand and batch number. 
 
Box 2: Practical safety monitoring in a clinical setting. 
1)  Black triangle drugs: biosimilar medicines are new medicines (black triangle), so any 
(suspected) ADRs need to be reported.  
2) Our team has completed a “yellow card report” for every patient experiencing an injection 
site reaction or pain/stinging after administering the adalimumab biosimilar Amgevita®. Our 
service incorporated this as a necessary requirement in patients who do not tolerate the 
biosimilar medicine and wish to switch back to the originator drug. 
 
As with all biologic medicines, collection of clinical outcomes should take place and 
prospectively be assessed to ensure quality of outcomes. Individual clinical teams should 
agree on the mechanisms of outcome data recording and collecting. Loss of biological 
activity after a switch from originator to biosimilar agent should be documented in a detailed 
fashion and, wherever possible, include anti-drug antibody monitoring. 
 
Box 3: Practical efficacy monitoring. 
1) Consider testing anti-drug antibody status (if the test is available) before switching to the 
new biosimilar medicine to allow future analysis of loss of efficacy in patients. Other factors, 
such as co-prescription of traditional DMARD or adherence to treatment should also be 
recorded. 
2) Monitor the reasons if patients request a switch back to the original molecule. In our 










treatment were issues with device acceptability and/or patients experiencing nocebo effects 
[44]. 
3) Nocebo effects may occur in any care setting and highlight the importance of 
communicating treatment changes clearly, including originator to biosimilar switched in 
practice [45-49]. 
 
However, testing for anti-drug antibodies causes added cost and thus may not be a viable 
option to allow this aspect of pharmacovigilance in all patients. 
Lastly, a patient experience survey in the form of a short questionnaire may be carried out 
before and after the implementation of biosimilar treatment to ensure that patient experience 
has not been negatively impacted. Findings should be shared nationally/internationally and 
used to support future commissioning decisions when relevant [35]. 
 
3.9 Tracking of savings and biosimilar adoption rate 
Although the establishment of biosimilar medicines should not be done solely for the purpose 
of cost saving, the potential drug budget savings are one of the main reasons behind 
biosimilar adoption across services and health care systems. 
 
Box 4: Practical considerations in the UK. 
In the UK, Medicines Optimization Commissioning for Quality and Innovation (CQUIN) 
targets agreed by Hospitals/Trusts will drive the adoption of biosimilar medicines into routine 
care.  
1) Percentage targets: a defined percentage target for mAbs naïve patients and (usually) a 
different (lower) percentage target for switching patients. These percentages may increase 
over time and Hospitals/Trusts who fail to meet these agreements will incur financial 
penalties [32,50] 
2) The patient should be at the center of all care, and as such the Regional Medicines 
Optimization Committee (RMOC) issued a statement with regards to the adalimumab 
biosimilar product and suggests that [45]: 
a) Where severe discomfort at the injection site is of significant concern, transition to another 
product may be appropriate.  
b) Where disease flares occur after switching to a biosimilar these are unlikely to reflect a 
failure of the biosimilar. Disease flares and a lack of sustained response happen commonly 
during treatment with the same product. Logically any lack of responsiveness (regardless of a 
recent switch) should prompt a discussion about changing the drug completely to a different 
biologic agent, but reverting to the originator drug is a possible initial step. If a flare is due 
to disease progression rather than lack of effect of the biosimilar (which is likely to be the 
majority of cases), going back to the originator will not make much difference and sooner or 
later the patient will move on to a different biologic agent. 
 
4. Effects of biosimilar introduction on prescribing behavior and access to treatment 
Looking at the process described above, it is apparent that adoption of biosimilar medicines is 
not a simple and straightforward process. Some services/centers may delay or avoid adoption 
of biosimilars, although potential financial penalties imposed are considerable deterrents. 
Nonetheless, offering “incentives” affecting our patient population may increase biosimilar 
use in Pediatrics. One of these incentives could be long-awaited increased access to biologic 
agents earlier in the treatment of JIA and/or other pediatric autoimmune/inflammatory 
conditions. Other incentives may target centers that are fast in adopting new biosimilar 
medicines, rewarding them with increments in budgets to employ staff needed in specific 










with concise and effective mechanisms for monitoring drug safety and outcomes. 
Unfortunately, to date, the adoption of biosimilar medicines has not translated to faster access 
to these medicines in Pediatric Rheumatology (at least in the UK and Germany, but likely 
also in other regions). 
 
Box 5: Prescribing and access to biosimilars in the UK. 
Rheumatology clinical teams spent a lot of time and effort switching patients to biosimilar 
medicines in the last years working on the premise that cost-efficiencies would lead to 
improved access to medicines. However, in the experience of the authors, it would seem 
unwise to expect changes in the near future with regards to early access to mAbs 
1) The NHS England pathway to treat JIA is unlikely to change the approach that (in most 
cases) a non-biologic DMARD requires to be trialed first [51]. 
2) Financial rewards for meeting Trust CQUIN targets, if available, often have to be shared 
between teams or need to be diverted to the individual Trust’s annual cost improvement 
targets.  
3) For Pediatric conditions rarer than JIA, where randomized clinical trials are not available 
to evaluate the efficacy of treatments, access to NHS England funded drugs has become even 
more complex over the past years. Individual Funding Requests (IFR) are rarely accepted 
based on the lack of “exceptionality” and therefore will be rejected [52]. Requests for Urgent 
Policy Proposals are likely to be rejected with “low levels of quality evidence”, which 
directly impacts Pediatric patients with rare conditions. Commissioning Through Evaluation 
might be available, but the overall process tends to be significantly time-consuming for the 
clinicians putting these requests forward and may take a long time to translate into access to 
medicines. 
4) The NHS (as other healthcare systems) is under significant financial strain with new high 
cost treatments being recently approved for pediatric patients with non-rheumatology 
conditions, such as the CFTR modulator drugs for cystic fibrosis and nusinersen for certain 
types of spinal muscular atrophy (SMA). 
 
Changes in the choice for first- or second-line biologic medicines may be more likely to 
occur. UK NICE guidelines for example state in the vast majority of their reviews that, where 
head to head trials determining efficacy between medicines are not available (and this is 


















Box 6: Potential short-term changes in access to biologic drugs 
A small number of examples of increased access to high cost drugs have materialized since 
the adoption of biosimilar medicines. 
1) Adalimumab may become the first line anti-TNF of choice, as it is now more cost-
effective than etanercept (especially in younger patients where biosimilar etanercept 
formulations are not available). 
2) Access to rituximab has increased in conditions such as juvenile dermatomyositis, where 
it is no longer necessary for patients to be treated with IV immunoglobulins in order to be 
eligible for rituximab. 
3) When the IL-6 inhibitor tocilizumab will become available as a biosimilar in the near 
future, and always guided by available clinical evidence, clinicians may find themselves 
able to choose freely between TNF-blockers and e.g. IL-6 inhibitors as first line treatments 
for JIA and other conditions., according to patient preferences and individual disease 
phenotype and progression or directed by pharmacogenomics.  
4) Individual Hospitals/Trusts are more likely to approve treatments for rare conditions not 
funded by NHS England using biosimilar mAbs if the cost is reasonable and potentially off-















Biosimilar pharmaceuticals have been introduced to Pediatric Rheumatology and are here to 
stay. We suggest a pathway the pediatric rheumatology MDT can use for the assessment and 
implementation of biosimilar medicines in individual Children’s Hospitals/Trusts, 
highlighting areas of importance in Pediatrics such as drug licensing, excipient analysis and 
administration device availability. Pharmacovigilance programs and patient satisfaction 
surveys should be considered as methods to monitor biosimilar safety, efficacy and 
acceptance in the Pediatric patient population. Ultimately, the more biosimilar medicines are 
made available, and the more competitive their prices become, the more likely the utopia of 
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7. Figure legends 
 
Figure 1: The principle of extrapolation and application of similarity (Reproduced with 
permission from [29] by courtesy of Springer Verlag GmbH). If a biosimilar product matches 
the originator molecule in its structural attributes, tested biological functions, PK and PD 
studies in humans for a sensitive indication, then, assuming similarity for all other non-tested 
indications can be justified. 
 
Figure 2: Development approach of biosimilar medicines compared to generic and 
originator biologic product. Reproduced with permission by courtesy of Springer Verlag 
Gmb. The figure shows how the development required for biosimilar products is much 
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Table 1: Etanercept biosimilar product assessment. Source: European Public Assessment 
Report (EMA); “soft” intelligence from PMSG and UKMI Written by S M Wong 
 Benepali® Erelzi® 
Manufacturer Biogen Sandoz 
Preparation 25mg pre-filled syringe (PFS) 
50mg Pen, PFS 
25mg PFS 
50mg Pen, PFS 
Pens 
NB: Enbrel pen 
involves pressing a 
button; 27 gauge 
needles 
Auto-injector device (pressing the 
pen against the skin) 
 
Needle sheath is latex-free 
 
Needle size – 27 Gauge ½ inch 
Senso-ready pen (pressing the pen against 
the skin) 
 
Needle sheath contains a derivative of 
latex 
 
Needle size –27 Gauge ½ inch 
License As Enbrel® preparations As Enbrel® preparations 
Clinical study Phase III, randomized, double-
blind, study in 596 subjects with 
moderate to severe RA despite 
methotrexate therapy 
No pediatric reference studies  
The PIII EGALITY trial comparing 
product with Enbrel® in 531 patients with 
moderate-severe chronic plaque psoriasis 
completed in March 2015.  
No pediatric reference studies 
Safety Similar between the two treatment 
groups and in line with the well-
characterized safety profile of 
Enbrel®  
The incidence of treatment-emergent 
adverse events up to week 52 was 
comparable between biosimilar product 
(59.8%) and Enbrel® (57.3%) 
Homecare 
 
- Pharma-funded service 
- Details of homecare services 
provided with each provider 
- Pharma-funded service 
- Details of homecare services provided 










dibasic dihydrate  
- Sucrose 
- Sodium chloride 
- Sodium dihydrogen phosphate 
monohydrate 
- Disodium hydrogen phosphate 
heptahydrate  
- Water for injections 
NB: Unlike Enbrel®, Benepali® 
does not contain L-arginine 
- Citric acid anhydrous  
- Sodium citrate dihydrate 
- Sodium chloride  
- Sucrose 
- L-Lysine hydrochloride 
- Sodium hydroxide (for pH 
adjustment)  
- Hydrochloric acid (for pH adjustment)  
- Water for injections 
NB: citric acid and sodium citrate are 
known to cause discomfort on injection 
Existing issues Despite full pediatric license granted to both products, no pediatric formulation 
has been developed (10mg vial or 25mg powder and solvent vial) for 
smaller/younger patients. If biosimilar is adopted, the originator should still be 
offered to some patients 
Outcome Benepali® biosimilar of choice due to excipients 
Current recommendations for BRAND choice are as follows: 
 Patients (new and old) who need doses <25mg: use Enbrel® (10mg or 25mg 
vials as appropriate) 
 Any new patient on a dose of 25mg and above will be offered Benepali® 
 Existing patients on an Enbrel® PFS or PEN will be informed on the Trust 
switching initiative and will be switched to Benepali® if agreed  










preparation will be consulted about the possibility of switching to a 25mg 
Benepali® PFS 
 Any patients over 16 years of age and a dose of 25mg or over will be 
switched to Benepali® to facilitate transition to adult care. 
 This guidance will be reviewed as new biosimilar preparations come into the 
UK market. 
***Unlicensed use of the biosimilar (i.e. decanting from the 25mg of 50mg 












Table 2: Adalimumab biosimilar product assessment. Source: European Public Assessment 
Report (EMA); “soft” intelligence from PMSG and UKMI Written by S M Wong 
 Amgevita® Imraldi® Cyltezo® 
Manufacturer Amgen Biogen Boehringer 
Presentation Sureclick Pen 40mg in 0.8mL 
27G 
20mg in 0.4mL and 40mg in 
0.8mL PFS, 27 and 29G 
Needle sheath in Pen contains 
a latex derivative 
40mg in 0.8mL Pen 
40mg in 0.8mL PFS 
 
No 20mg preparation 
40mg Autoinjector pen 
in 0.8mL 
40mg in 0.8mL PFS 
No 20mg preparation 
Needle sheath in Pen 
contains a latex 
derivative 
License As Humira® except pediatric 
uveitis 
As Humira® except 
pediatric uveitis 




Available via EMA in RA 
patients 
No paediatric reference 
studies 
Available via EMA in 
RA patients 
No paediatric reference 
studies 
Available via EMA in 
RA patients 
No paediatric reference 
studies 
Safety As above 








to old Humira® 
formulation) 
Homecare Pharma-funded Pharma-funded Pharma-funded 
Excipients Glacial acetic acid, sucrose, 












acetic acid. Trehalose 
dehydrate, polysorbate 
80 and water 
Citrate free 
Existing issues Amgevita® only product with 20mg pediatric preparation 
None of them licensed in pediatric uveitis: potential use off-label or keep 
originator 
Pain/device comparison studies used Humira® old preparation for comparison 
Concentration: half of Humira® = larger volume of injection 
Humira® introduced 3 changes to their formulation: 27 to 29G needle, removal 
of citrate and reduction of injection volume. Pediatric patients consistently 
reported better tolerability of this formulation VS the old one in our unit. 
Amgevita® and Cyltezo® are citrate free, however, needle gauge in some of the 
products is still 27G and the volume remains the same as the old Humira® 
formulation. It remains to be seen whether removing the citrate alone will lead to 
a similar patient experience as with the new Humira® formulation 
Outcome Trial of Amgevita® (citrate free and pediatric formulations) in new patients. If no 
issues reported, offer switch to existing patients. 












Table 3: Available options to inform patients who are switching from originator products 
to biosimilar products. An example of a patient information letter can be found in Appendix 
B 
Option Positive aspects Negative aspects 
Focus groups prior to 
adoption 
Open,  
face to face 
Difficult to organize 
Could be costly if facilities or 
catering need to be booked 
Logistic issues if large 
number of patients on the 
drug 
One to one patient/carer 
consultation with trained 
clinician 
Face to face 
Opportunity to ask questions 
in a private environment 
Time consuming (could take 
away time from clinic 
review) 
Patients might take a long 
time to be due a clinic visit 
delaying biosimilar 
implementation 
Availability of rooms for 
consultation 
Distribution of patient 
information leaflets with 
contact details of relevant 
professionals within the 
MDT (nurse specialists, 
pharmacists) 
Suitable for large patient 
numbers  
Suitable for patients who are 
being treated at home 
Avoid delays in 
implementation of biosimilar 
Not face to face 
Relays on the patient to 
contact team if there are any 
issues/worries 
Does not capture potential 
technique training needs 














 Biologic therapeutics are manufactured in biological sources 
 Biosimilars are altered versions of the not patent protected innovator drug 
 Significant concerns exist in the adoption of drugs not trialed in children 
 Real-life data on drug safety and efficacy need to be collected to increase evidence base 
 Despite all concerns, biosimilars may improve access to biologics in Pediatric 
rheumatology 
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